Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:XBIT

XBiotech 5/14/2026 Earnings Report

XBiotech logo
$2.48 +0.09 (+3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$2.53 +0.05 (+2.18%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

XBiotech EPS Results

Actual EPS
-$0.18
Consensus EPS
$0.03
Beat/Miss
Missed by -$0.21
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

XBiotech Earnings Headlines

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar
May 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/xbiotechs-new-axial-spondyloarthritis-trial-puts-vilamakitug-on-investors-radar?utm_source=marketbeat.com&utm_medium=referral
XBiotech (XBIT) to Release Earnings on Tuesday
May 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30769403
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
May 21 at 1:00 AM  |  American Alternative (Ad)
XBiotech: Q4 Earnings Snapshot
March 13, 2026  |  chron.comhttps://www.chron.com/business/article/xbiotech-q4-earnings-snapshot-22075535.php
XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?
October 28, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/xbiotech-s-new-trial-a-potential-game-changer-for-rheumatoid-arthritis-treatment/ar-AA1PitPW
XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
August 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/xbiotech-inc-nasdaq-xbit-top-100425873.html
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT) is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company’s core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech’s lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company’s most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients. Data from these studies demonstrated potential benefits in overall survival, symptom control and quality of life measures. XBiotech is also exploring Xilonix® in additional oncology settings as well as in post-surgical inflammation and other conditions driven by IL-1α–mediated pathways.

Beyond its lead candidate, XBiotech is advancing a diversified pipeline of True Human™ antibodies against novel targets in both oncology and inflammatory diseases. The company conducts clinical development programs in North America and Europe, collaborating with research hospitals and cancer centers to evaluate therapeutic potential across multiple indications. Preclinical studies are ongoing to expand the platform into other areas of unmet medical need.

Founded in 2005 by entrepreneur John Simard, XBiotech is headquartered in Austin, Texas, with research operations in Canada and Europe. Laurent Fischer serves as Chief Executive Officer, overseeing corporate strategy, clinical development and manufacturing partnerships. The company’s leadership combines expertise in antibody engineering, clinical oncology and regulatory affairs to advance its pipeline toward potential commercialization.

View XBiotech Profile
Earnings Tools